HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $5.75 price target on the stock. HC Wainwright’s target price points to a potential upside of 122.87% from the company’s previous close.

Separately, BTIG Research started coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Stock Up 3.2 %

Shares of NASDAQ:VYNE traded up $0.08 during trading on Monday, hitting $2.58. The stock had a trading volume of 69,228 shares, compared to its average volume of 81,556. The stock has a market capitalization of $38.06 million, a price-to-earnings ratio of -3.00 and a beta of 1.37. VYNE Therapeutics has a 12-month low of $1.57 and a 12-month high of $3.43. The stock has a 50-day simple moving average of $2.70 and a two-hundred day simple moving average of $2.20.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up approximately 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics as of its most recent filing with the Securities & Exchange Commission. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.